Disease Information
General Information of the Disease (ID: DIS00035)
| Name |
Fungal meningitis
|
|---|---|
| ICD |
ICD-11: 1D01
|
| Resistance Map |
Type(s) of Resistant Mechanism of This Disease
Drug Resistance Data Categorized by Drug
Approved Drug(s)
3 drug(s) in total
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: Lanosterol 14-alpha demethylase (ERG11) | [1] | |||
| Resistant Disease | Cryptococcal meningitis [ICD-11: 1D01.0] | |||
| Molecule Alteration | Missense mutation | p.G484S (c.G1855T) |
||
| Resistant Drug | Fluconazole | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Cryptococcus neoformans stiain CN-5 | 5207 | ||
| Experiment for Molecule Alteration |
Genomic sequence assay | |||
| Experiment for Drug Resistance |
Microdilution and E-test methods assay | |||
| Mechanism Description | A point mutation (G1855T) in the ERG11 gene was detected in the FCZ-resistant isolate (CN-5) only. And this mutation is responsible for the amino acid substitution glycine 484 for serine (G484S) in the ERG11 deduced protein sequence of C. neoformans. | |||
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: ABC transporter (ABCT) | [2] | |||
| Sensitive Disease | Cryptococcal meningitis [ICD-11: 1D01.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Sensitive Drug | Fluconazole | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Cryptococcus neoformans stiain BPY22.17 | 5207 | ||
| Experiment for Molecule Alteration |
Southern hybridization analysis; Northern hybridization analysis | |||
| Experiment for Drug Resistance |
Rhodamine 6G accumulation assay; M27-A assay | |||
| Mechanism Description | We found that the MIC to fluconazole in the knock-out mutant cnafr reduced 16-fold compared to the parent strain BPY22.17, but was nearly equal to that of the matched fluconazole-susceptible strain BPY22 (although was still somewhat less susceptible than strain BPY22). | |||
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: ABC transporter (ABCT) | [2] | |||
| Sensitive Disease | Cryptococcal meningitis [ICD-11: 1D01.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Sensitive Drug | Itraconazole | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Cryptococcus neoformans stiain BPY22.17 | 5207 | ||
| Experiment for Molecule Alteration |
Southern hybridization analysis; Northern hybridization analysis | |||
| Experiment for Drug Resistance |
Rhodamine 6G accumulation assay; M27-A assay | |||
| Mechanism Description | Again, disruption of CnAFR1 gene resulted in an increased susceptibility to ketoconazole and itraconazole, suggesting that these antifungal azoles are substrates for CnAfr1p. | |||
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: ABC transporter (ABCT) | [2] | |||
| Sensitive Disease | Cryptococcal meningitis [ICD-11: 1D01.0] | |||
| Molecule Alteration | Expression | Down-regulation |
||
| Sensitive Drug | Ketoconazole | |||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | Cryptococcus neoformans stiain BPY22.17 | 5207 | ||
| Experiment for Molecule Alteration |
Southern hybridization analysis; Northern hybridization analysis | |||
| Experiment for Drug Resistance |
Rhodamine 6G accumulation assay; M27-A assay | |||
| Mechanism Description | Again, disruption of CnAFR1 gene resulted in an increased susceptibility to ketoconazole and itraconazole, suggesting that these antifungal azoles are substrates for CnAfr1p. | |||
References
visits since 2022
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.
